Kardigan, Inc.(KARD)

Biotechnology · Princeton, NJ

$13.49-1.75 (-11.48%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

PS Ratio: N/A

Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.

The P/S ratio is N/A as of 2026-10-06T22:51:43.513Z.

Stored calculation inputs

Calculation as of: 2026-10-06T22:51:43.513Z.

Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 1,205,184,742
TTM revenue · period ending 2026-06-30: N/A

FMP input reference: 6dd2a4984e4340952b62e9ecd156f35eed99e3c78779d37ae6f95d3f5c845125

P/E Ratio|Gross Margin|Revenue Growth|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

KARD PS Ratio Metrics

PS RATIO

N/A

KARD Competitors' PS Ratio

KARD

Kardigan, Inc.

Current

Market Cap

$1.21B

PS Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

DMRA

Damora Therapeutics, Inc.

vs KARD

Market Cap

$1.20B

PS Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

TYRA

Tyra Biosciences, Inc.

vs KARD

Market Cap

$1.21B

PS Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

INNV

Innovage Holding Corp.

vs KARD

Market Cap

$1.22B

PS Ratio

1.23

TTM Avg

1.18

3Y Avg

0.95

5Y Avg

1.06

MNKD

MannKind Corporation

vs KARD

Market Cap

$1.18B

PS Ratio

3.01

TTM Avg

3.95

3Y Avg

5.37

5Y Avg

8.24

CRON

Cronos Group Inc.

vs KARD

Market Cap

$1.23B

PS Ratio

5.45

TTM Avg

6.20

3Y Avg

7.49

5Y Avg

10.16

OMDA

Omada Health

vs KARD

Market Cap

$1.23B

PS Ratio

3.98

TTM Avg

4.15

3Y Avg

4.52

5Y Avg

4.52

ORIC

ORIC Pharmaceuticals, Inc.

vs KARD

Market Cap

$1.24B

PS Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NKTR

Nektar Therapeutics

vs KARD

Market Cap

$1.14B

PS Ratio

20.97

TTM Avg

23.60

3Y Avg

9.65

5Y Avg

9.36

AMPH

Amphastar Pharmaceuticals, Inc.

vs KARD

Market Cap

$1.14B

PS Ratio

1.56

TTM Avg

1.49

3Y Avg

2.58

5Y Avg

3.06

NAME	MARKET CAP	PS RATIO	TTM	3Y	5Y
Kardigan, Inc. (KARD)	$1.21B	N/A	N/A	N/A	N/A
Damora Therapeutics, Inc. (DMRA)vs ›	$1.20B	N/A	N/A	N/A	N/A
Tyra Biosciences, Inc. (TYRA)vs ›	$1.21B	N/A	N/A	N/A	N/A
Innovage Holding Corp. (INNV)vs ›	$1.22B	1.23	1.18	0.95	1.06
MannKind Corporation (MNKD)vs ›	$1.18B	3.01	3.95	5.37	8.24
Cronos Group Inc. (CRON)vs ›	$1.23B	5.45	6.20	7.49	10.16
Omada Health (OMDA)vs ›	$1.23B	3.98	4.15	4.52	4.52
ORIC Pharmaceuticals, Inc. (ORIC)vs ›	$1.24B	N/A	N/A	N/A	N/A
Nektar Therapeutics (NKTR)vs ›	$1.14B	20.97	23.60	9.65	9.36
Amphastar Pharmaceuticals, Inc. (AMPH)vs ›	$1.14B	1.56	1.49	2.58	3.06

How this was calculated

The four-quarter calculation detail is unavailable for this stored observation.

The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.

These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.

Sales Valuation

P/S Ratio

N/A

Market Cap / Trailing Twelve-Month Revenue

PS Ratio Formula & Definition

PS Ratio = Market Cap / Revenue (TTM)

The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

PS Ratio: N/A

KARD PS Ratio Metrics

KARD Competitors' PS Ratio

Sales Valuation

PS Ratio Formula & Definition

Related Metrics